Real-World data shows promise for lenvatinib in advanced liver cancer

NCT ID NCT07298538

Ongoing Knowledge-focused Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at medical records from 800 patients with unresectable liver cancer who were treated with lenvatinib-based therapy at six hospitals. Researchers analyzed how long patients survived, how well the cancer responded, and any side effects. The goal is to better understand real-world outcomes for this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenvatinib
What this could lead to: If successful, this study could confirm lenvatinib-based therapy as a standard option for extending survival in patients with unresectable liver cancer.
What could go wrong: This is a retrospective review, not a controlled trial, so results may be influenced by patient selection and other factors. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNRESECTABLE HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Tianjin Medical University Cancer Institute and Hospital

Tianjin, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.